Metabolomic score in patients from the CANONIC Study. Validation in patients from the PREDICT Study.
Richard Moreau (EF Clif. Barcelona, Spain)
Christophe Junot (CEA. Saclay, France)
Promoter: EF Clif
Start date: 01/01/2020
End date: 31/12/2020
Untargeted blood metabolomics performed in 831 patients with acutely decompensated (including 181 with ACLF) revealed a 38-metabolite signature that was distinctive of ACLF versus no ACLF (J Hepatol 2020;72:688-701). The objective of the study was to validate the 38-metabolite signature previously found in the CANONIC Study among 800 patients with acutely decompensated cirrhosis enrolled in the PREDICT study. Within 2020, the analysis of blood metabolomics was completed. The results show that 36 of the 38 metabolites has a discriminative accuracy for distinguishing patients with poor outcomes (development of ACLF, death) from those with better outcomes. A report of the results is under preparation.